TG Therapeutics Inc (NASDAQ:TGTX)

41.62
Delayed Data
As of 3:59pm ET
 -1.11 / -2.60%
Today’s Change
6.34
Today|||52-Week Range
56.74
-19.99%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$6.0B

Company Description

TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.

Contact Information

TG Therapeutics, Inc.
2 Gansevoort Street
New York New York 10014
P:(212) 554-4484
Investor Relations:
1212

Employees

Shareholders

Mutual fund holders39.08%
Other institutional34.81%
Individual stakeholders16.19%

Top Executives

Michael Sean WeissExecutive Chairman, President & CEO
Sean A. PowerChief Financial Officer, Secretary & Treasurer
Owen A. O'ConnorChief Scientific Officer
Adam WaldmanChief Commercial Officer
Jenna A. BoscoSenior Vice President-Corporate Communications